This webinar introduces a simplified approach to multiplex protein detection: no antibody conjugation, no iterative staining, and a single staining cycle built on standard workflows you already know. You'll see how this reduces assay setup time and lowers the barrier to building custom panels. You'll also hear directly from an experienced spatial biology service laboratory about what it actually takes to validate a new multiplex workflow for real-world use, including early results from an antibody-drug conjugate (ADC) panel now in development, and the repeatability and robustness data behind it.
Multiplex immunofluorescence should accelerate biomarker discovery, not slow it down with antibody conjugation, iterative staining cycles, and months of panel optimization. For many translational and pharma research teams, these barriers make custom multiplex panels difficult to develop, validate, and scale.
This webinar introduces a simplified approach to multiplex protein detection: no antibody conjugation, no iterative staining, and a single staining cycle built on standard workflows you already know. You'll see how this reduces assay setup time and lowers the barrier to building custom panels. You'll also hear directly from an experienced spatial biology service laboratory about what it actually takes to validate a new multiplex workflow for real-world use, including early results from an antibody-drug conjugate (ADC) panel now in development, and the repeatability and robustness data behind it.
Whether you're building a panel in-house or evaluating a validated service partner, you'll leave with a clearer picture of what's possible now, and what to look for as you move forward.
Kelly Hunter is Chief Scientific Officer at Propath UK, where he leads the company’s scientific strategy and development of advanced spatial biology services across spatial proteomics, spatial transcriptomics, multiplex immunofluorescence and single-cell spatial analysis. With substantial experience in implementing and commercialising cutting-edge tissue profiling technologies, Kelly works closely with pharmaceutical and biotechnology partners to design translational research and biomarker strategies that generate meaningful, decision-ready data from limited clinical samples. His expertise spans complex assay development, custom high-plex panel design, spatial multiomics workflows and the integration of robust bioinformatics to translate rich tissue data into actionable biological insight. At Propath, Kelly helps clients apply responsive, GCP-compliant spatial biology solutions to support mechanism-of-action studies, biomarker discovery, clinical trial delivery and confident decision-making across the drug development pipeline.
